A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
Public ClinicalTrials.gov record NCT00404612. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
Study identification
- NCT ID
- NCT00404612
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Lux Biosciences, Inc.
- Industry
- Enrollment
- 218 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- LX211 Drug
Drug
Eligibility (public fields only)
- Age range
- 13 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2006
- Primary completion
- Oct 31, 2008
- Completion
- Apr 30, 2009
- Last update posted
- Oct 10, 2012
2007 – 2009
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| Retinal Consultants of Arizona | Phoenix | Arizona | 85014 | — |
| University of Illinois - Chicago | Chicago | Illinois | 60612 | — |
| Midwest Eye Institute | Indianapolis | Indiana | 46280 | — |
| Wilmer Eye Institute | Baltimore | Maryland | 21287 | — |
| Massachusetts Eye and Ear Infirmary | Boston | Massachusetts | 02114 | — |
| Massachusetts Eye Research and Surgery Institute | Cambridge | Massachusetts | 02142 | — |
| Associated Retinal Consultants, PC | Grand Rapids | Michigan | 49546 | — |
| Tauber Eye Center | Kansas City | Missouri | 64111 | — |
| UMDNJ-New Jersey Medical School, Ophthalmology Dept. | Newark | New Jersey | 07103 | — |
| New York Eye & Ear Hospital | New York | New York | 10003 | — |
| Duke University Eye Center, Erwin Road | Durham | North Carolina | — | — |
| Oregon Health Sciences University | Portland | Oregon | 97201 | — |
| Texas Retina Associates | Arlington | Texas | 76012 | — |
| Retina Research Center | Austin | Texas | 78705 | — |
| Texas Retina Associates | Dallas | Texas | 75231 | — |
| Vitreoretinal Consultants | Houston | Texas | 77030 | — |
| Retina & Uveitis Consultants of Texas | San Antonio | Texas | 78240 | — |
| Viginia Eye Consultants | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00404612, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 10, 2012 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00404612 live on ClinicalTrials.gov.